UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) 5858 HORTON STREET #455 EMERYVILLE, California 94608 (Address of Principal Executive Offices) (Zip Code) (Commissio ...

EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular TherapeuticsÂÂ (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a strategically focused pipeline, updated Phase 3 4FRONT program plans, initial 4FRONT guidance and resulting updated cash runway guidance. "4DMT was founded to address the challenges posed by traditional AAVs and to bring genetic me ...

EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a strategically focused pipeline, updated Phase 3 4FRONT program plans, initial 4FRONT guidance and resulting updated cash runway guidance. "4DMT was founded to address the challenges posed by traditional AAVs and to bring genetic medi ...

EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular TherapeuticsÂÂ (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in diabetic macular edema (DME) and alignment with the U.S. Food and Drug Administration (FDA) on registrational pathway for 4D-150 in DME. "Th ...

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT's Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and transformative genetic medicinesProprietary intravitreal vector R100 demonstrated superior transduction and transgene expression compared to AAV2, the standard AAV serotypes used in retinal gene therapies, in all three human retinal cell types evaluated in vitro (up to ~10-fold improvement), and in all primate retinal ...

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.91%. A quarter ago, it was expected that this company would post a loss of $0.72 per share when it actually produced a loss of $0.63, delivering a surprise of 12.50%.Over the last four quarters, the com ...

营收情况 - 2024年第三季度营收较2023年同期减少2020.1万美元降幅100%[169] - 2024年前三季度营收较2023年同期减少2070.6万美元降幅100%[167] 净亏损情况 - 2024年前三季度净亏损11120万美元2023年为6860万美元[153] - 2024年第三季度净亏损4380万美元2023年为1030万美元[153] - 截至2024年9月30日累计赤字5.265亿美元[153] 研发费用 - 2024年前三季度研发费用较2023年增加2714.4万美元涨幅38%[167] - 2024年第三季度研发费用较2023年增加1341.8万美元涨幅54%[169] - 2024年第三季度研发费用较2023年同期增加1340万美元涨幅54%[173] - 2024年前三季度研发费用较2023年同期增加2710万美元涨幅38%[174] 管理费用 - 2024年前三季度管理费用较2023年增加765.9万美元涨幅30%[167] - 2024年第三季度管理费用较2023年增加353.9万美元涨幅39%[169] - 2024年第三季度管理费用较2023年同期增加350万美元涨幅39%[175] - 2024年前三季度管理费用较2023年同期增加770万美元涨幅30%[176] 其他净收入 - 2024年第三季度其他净收入较2023年同期增加360万美元涨幅96%[177] - 2024年前三季度其他净收入较2023年同期增加1290万美元涨幅168%[177] 现金及资本情况 - 2024年2月完成公开发行净收益2.812亿美元[149] - 截至2024年9月30日公司拥有现金、现金等价物和有价证券共5.507亿美元[188] - 2024年9月30日公司有现金及现金等价物和有价证券共5.507亿美元[215] - 公司现有现金可支撑至少一年计划运营[194] 未来费用预期 - 公司预计研发和管理费用在可预见未来将持续增加[190] - 公司预计未来资本支出将显著增加[190] 投资活动现金情况 - 2024年前九个月投资活动使用的净现金为3.095亿美元其中购买有价证券4.099亿美元购买房产设备280万美元被1.032亿美元有价证券到期所抵消[202] - 2023年前九个月投资活动提供的净现金为1.224亿美元源于1.448亿美元有价证券到期被2020万美元有价证券购买和220万美元房产设备购买所抵消[202] 融资活动现金情况 - 2024年前九个月融资活动提供的净现金为3.366亿美元主要源于公开发行普通股的收益3.161亿美元等[203] - 2023年前九个月融资活动提供的净现金为1.521亿美元主要源于公开发行普通股收益1.292亿美元等[203] 公司类型相关 - 截至2025年12月31日公司将一直是新兴成长型公司[213] - 公司将利用JOBS法案下的豁免权延迟采用新的或修订的会计准则[211] 利率与通货膨胀影响 - 利率立即10%的变化不会对公司现金等价物或有价证券的公允价值产生重大影响[215] - 公司认为通货膨胀或利率变化对运营结果无重大影响[216]

财务状况 - 截至2024年9月30日现金、现金等价物和有价证券为5.51亿美元预计至少可支撑运营至2027年上半年[1][9] - 2024年第三季度净亏损为4380万美元2023年第三季度净亏损为1030万美元[11] 费用情况 - 2024年第三季度研发费用为3850万美元较2023年第三季度的2510万美元有所增加[10] - 2024年第三季度一般及行政费用为1270万美元较2023年第三季度的910万美元有所增加[11] 临床试验进展（4D - 150相关） - 4D - 150在湿性年龄相关性黄斑变性（wet AMD）的PRISM 1/2期临床试验中呈现积极中期数据计划的3期剂量（3E10 vg/眼）在所有研究人群中抗VEGF注射治疗负担降低83%（严重人群）[5] - 4D - 150在湿性年龄相关性黄斑变性（wet AMD）的PRISM 1/2期临床试验中预计52周无注射率在广泛人群和新确诊人群中分别为70%和87%[5] - 4D - 150的4FRONT - 1 3期临床试验预计于2025年第一季度启动[1][5][8] - 4D - 150用于糖尿病性黄斑水肿（DME）的SPECTRA临床试验项目和中期数据预计于2025年1月初更新[1][8] 临床试验进展（4D - 175相关） - 4D - 175用于地理萎缩的1期试验预计于2025年第一季度开始招募[8] 团队建设 - 扩充高级眼科领导团队[2]

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar to approved anti-VEGF agents  4D-150 4FRONT Phase 3 program in wet AMD designed to maximize probability of success, continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025 Continuing KOL engagement to expand awarene ...

4D Molecular Therapeutics, Inc. (FDMT) has been beaten down lately with too much selling pressure. While the stock has lost 26% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a mo ...